Halberd Corp. (OTC: HALB) and Mississippi State Un
Post# of 630
(Total Views: 215)
Posted On: 06/11/2022 8:20:56 AM
Halberd Corp. (OTC: HALB) and Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
https://topnewsguide.com/2022/06/09/halberd-c...ification/
Med Tech Reporter® IPA/IPA.V – THRM.V/TBRIF – PBIO
Over the course of the past months, the healthcare company Halberd Corporation (OTC: HALB) has managed to hit a wide range of milestones in its research and development activities. That brought the stock to the attention of investors in a big way and yesterday, the company was in the news once again after it made a major announcement.
The company announced yesterday that it had completed a non-disclosure agreement along with Mississippi State University. The NDA in question is related to the next steps in animal testing so that Halberd could obtain a certificate from the United States Food and Drug Administration for its extracorporeal disease eradication procedure. It ought to be noted that the process has already been patented.
In this context, it should be noted that back on May 18, 2022 it had been announced by Halberd that it had engaged the services of mdi Consultants for the purposes of getting suitable assistance with regards to the FDA application. At the time, the company had been consulting with mdi and the FDA for the specific purposes of finding out the requirements of the animal testing process. Yesterday, Halberd announced that it was going to go about the animal testing process as per the processes laid down by the FDA so that the available funds for the whole operation is spent wisely.
Investors need to keep in mind that the company has already been successful in completing the proof of concept testing of its extracorporeal disease eradication process. Some of the testings included the testing of the process with inflammatory cytokines, bacteria and a range of neurodegenerative disease antigens. At this point in time, it could be a good idea for investors to consider adding the Halberd stock to their watch lists and watch for the developments on this particular front.
The Med-Tech Reporter shows a list of companies in this stock classification.
https://www.thestreetnow.com/spotlight/medtechreport/
https://topnewsguide.com/2022/06/09/halberd-c...ification/
Med Tech Reporter® IPA/IPA.V – THRM.V/TBRIF – PBIO
Over the course of the past months, the healthcare company Halberd Corporation (OTC: HALB) has managed to hit a wide range of milestones in its research and development activities. That brought the stock to the attention of investors in a big way and yesterday, the company was in the news once again after it made a major announcement.
The company announced yesterday that it had completed a non-disclosure agreement along with Mississippi State University. The NDA in question is related to the next steps in animal testing so that Halberd could obtain a certificate from the United States Food and Drug Administration for its extracorporeal disease eradication procedure. It ought to be noted that the process has already been patented.
In this context, it should be noted that back on May 18, 2022 it had been announced by Halberd that it had engaged the services of mdi Consultants for the purposes of getting suitable assistance with regards to the FDA application. At the time, the company had been consulting with mdi and the FDA for the specific purposes of finding out the requirements of the animal testing process. Yesterday, Halberd announced that it was going to go about the animal testing process as per the processes laid down by the FDA so that the available funds for the whole operation is spent wisely.
Investors need to keep in mind that the company has already been successful in completing the proof of concept testing of its extracorporeal disease eradication process. Some of the testings included the testing of the process with inflammatory cytokines, bacteria and a range of neurodegenerative disease antigens. At this point in time, it could be a good idea for investors to consider adding the Halberd stock to their watch lists and watch for the developments on this particular front.
The Med-Tech Reporter shows a list of companies in this stock classification.
https://www.thestreetnow.com/spotlight/medtechreport/
(0)
(0)